FIRST REGULAR SESSION

HOUSE BILL NO. 1244

101ST GENERAL ASSEMBLY

INTRODUCED BY REPRESENTATIVE MAYHEW.

1495H.02I DANA RADEMAN MILLER, Chief Clerk

AN ACT

To amend chapters 334 and 338, RSMo, by adding thereto two new sections relating to management of medication risks.

Be it enacted by the General Assembly of the state of Missouri, as follows:

Section A. Chapters 334 and 338, RSMo, are amended by adding thereto two new sections, to be known as sections 334.115 and 338.087, to read as follows:

334.115. 1. Any physician who prescribes a drug for which the federal Food and Drug Administration has issued a boxed warning under 21 CFR 201.57(c)(1) to alert prescribers to an increased risk of suicidal ideation or behavior associated with the drug that is applicable to the patient may advise the patient of this increased risk, counsel the patient on how to recognize symptoms that may indicate the emergence of suicidal ideation or behavior, and provide the patient with the telephone number for the National Suicide Prevention Lifeline.

2. The prescribing physician or any other health care professional, as defined in section 376.1350, who works at a facility or clinic with which the prescribing physician is associated may conduct a follow-up interview with the patient four weeks after the issuance of the prescription if the prescription constitutes an initial prescription, as defined in section 195.010, or the first prescription issued for the patient after the effective date of this section. During the follow-up interview, the prescribing physician or other health care professional may screen the patient for signs of suicidal ideation or behavior and provide the patient with the telephone number for the National Suicide Prevention Lifeline. The follow-up interview may be conducted by means of telehealth as described in section 191.1145.

EXPLANATION — Matter enclosed in bold-faced brackets **[**thus**]** in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

338.087. 1. Any pharmacist who dispenses a drug for which the federal Food and Drug Administration has issued a boxed warning under 21 CFR 201.57(c)(1) to alert prescribers to an increased risk of suicidal ideation or behavior associated with the drug that is applicable to the patient may advise the patient of this increased risk and counsel the patient on how to recognize symptoms that may indicate the emergence of suicidal ideation or behavior.

2. The dispensing pharmacist shall not be required to counsel a patient if the patient refuses counseling.

3. The counseling described in this section shall not be required for inpatients of a hospital, institution, or other setting where other licensed or certified health care professionals are authorized to administer medications.

✓